Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and maximum tolerated dose of GRN163L in
treating patients with refractory or relapsed chronic lymphoproliferative disease.